stockrow
Friday 6 November 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
313.98
12.31
−3.77%
Follow CRL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1,681 | 1,858 | 2,266 | 2,621 | 2,924 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,977 | +10.2% | 3,917 | 4,016 | 4,251 | +1.9% | |
| Gross margin, % | 38.30 | 37.73 | 37.07 | 36.56 | 36.72 | 37.70 | 36.79 | 36.39 | 32.88 | 32.96 | 33.33 | (5.3) pt | ||||||
| EBT | 223 | 297 | 282 | 304 | 447 | 481 | 623 | 581 | 93 | (100) | (100) | n/m | ||||||
| EBT margin, % | 13.26 | 15.99 | 12.43 | 11.60 | 15.29 | 13.58 | 15.67 | 14.08 | 2.30 | (2.48) | (2.52) | (15.7) pt | ||||||
| Net income | 156 | 125 | 229 | 254 | 365 | 399 | 493 | 480 | 25 | (142) | 43 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 35.76 | 39.12 | 47.26 | 53.79 | 59.01 | 70.39 | 78.25 | 80.61 | 78.82 | 81.01 | 83.19 | +9.5% | |||||
| Earnings | 3.29 | 2.60 | 4.72 | 5.17 | 7.35 | 7.77 | 9.57 | 9.27 | 0.20 | (2.91) | 1.05 | n/m | ||||||
| Cash flow | 6.74 | 6.70 | 9.20 | 9.87 | 11.03 | 15.13 | 12.19 | 13.35 | 14.30 | 14.88 | 13.02 | +9.2% | ||||||
| Capex | (1.18) | (1.74) | (2.92) | (2.88) | (3.36) | (4.55) | (6.39) | (6.22) | (4.53) | (4.42) | (4.66) | +15.9% | ||||||
| Free cash flow | 5.56 | 4.96 | 6.28 | 6.99 | 7.67 | 10.58 | 5.80 | 7.13 | 9.76 | 10.46 | 8.36 | +7.3% | ||||||
| Book value | 17.85 | 22.06 | 27.53 | 33.61 | 42.75 | 50.48 | 58.67 | 70.32 | 67.48 | 63.96 | 67.61 | +15.2% | ||||||
| Shares, m | 47 | 47 | 48 | 49 | 50 | 50 | 51 | 51 | 51 | 50 | 49 | +0.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 23.19 | 42.72 | 24.08 | 29.55 | 34.04 | 48.49 | 22.82 | 25.30 | 1,025.56 | 0.00 | 300.09 | 127.6 | |||||
| P/S | 2.14 | 2.83 | 2.39 | 2.84 | 4.23 | 5.35 | 2.79 | 2.91 | 2.34 | 2.46 | 3.77 | 3.0 | ||||||
| P/B | 4.29 | 5.02 | 4.11 | 4.55 | 5.84 | 7.46 | 3.72 | 3.33 | 2.74 | 3.12 | 4.64 | 4.4 | ||||||
| EV/Sales | 2.80 | 3.36 | 3.04 | 3.47 | 4.83 | 6.05 | 3.41 | 3.48 | 2.85 | 2.94 | 4.34 | 3.6 | ||||||
| EV/FCF | 18.02 | 26.46 | 22.91 | 26.71 | 37.19 | 40.24 | 46.02 | 39.34 | 22.99 | 22.78 | 43.18 | 30.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 317 | 318 | 441 | 481 | 547 | 761 | 620 | 684 | 735 | 738 | 622 | +9.8% | |||||
| Capex | (55) | (82) | (140) | (141) | (167) | (229) | (325) | (319) | (233) | (219) | (223) | +16.5% | ||||||
| Free cash flow | 262 | 236 | 301 | 340 | 380 | 532 | 295 | 365 | 502 | 518 | 400 | +7.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 227 | 363 | 340 | 311 | 361 | 241 | 347 | 554 | 409 | 327 | 446 | +4.1% | |||||
| Net debt | 1,117 | 981 | 1,473 | 1,650 | 1,751 | 2,422 | 2,474 | 2,370 | 2,046 | 1,923 | 2,243 | +6.2% | ||||||
| Shareholders’ equity | 839 | 1,047 | 1,320 | 1,638 | 2,118 | 2,539 | 2,981 | 3,602 | 3,467 | 3,170 | 3,232 | +15.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 6.48 | 4.37 | 6.67 | 5.90 | 7.15 | 6.25 | 6.65 | 6.01 | 0.13 | (1.97) | 0.54 | (8.4) pt | |||||
| ROIC | 7.59 | 8.88 | 7.42 | 6.67 | 6.99 | 7.43 | 7.46 | 6.46 | 2.58 | 0.31 | 1.81 | (7.3) pt | ||||||
| ROE | 19.63 | 13.08 | 19.13 | 17.04 | 19.40 | 16.79 | 17.62 | 14.42 | 0.29 | (4.35) | 1.21 | (24.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 11,000 | 11,800 | 14,700 | 17,100 | 18,400 | 20,000 | 21,400 | 21,800 | 20,100 | 19,700 | — | +6.7% | |||||
| Revenue/emp, $m | 0.15 | 0.16 | 0.15 | 0.15 | 0.16 | 0.18 | 0.19 | 0.19 | 0.20 | 0.20 | — | +3.2% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Business profile
Where the money comes from and where it goes Fiscal 2024
| DSA | 2,451 | 60.53% |
|---|---|---|
| RMS | 829 | 20.48% |
| Manufacturing | 769 | 19.00% |
| Gross margin | 32.88% | |
| Operating margin | 5.61% | |
| Pre-tax margin | 2.30% |
Charles River Laboratories International, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ILMN Illumina, Inc. | $31.5B | 35.6× | 46.4× | +4.15% (above 0%: growing) | +48.98% (above 0%: growing) | +49.80% (above 0%: growing) | 73.52% | 27.02% | Compare |
| LH Labcorp Holdings Inc. | $29.5B | 29.5× | 26.7× | +6.92% (above 0%: growing) | +3.18% (above 0%: growing) | +44.73% (above 0%: growing) | 29.08% | 10.55% | Compare |
| DGX Quest Diagnostics Incorporated | $28.0B | 25.0× | 24.4× | +9.98% (above 0%: growing) | +29.36% (above 0%: growing) | +6.21% (above 0%: growing) | 33.65% | 15.47% | Compare |
| GH Guardant Health, Inc. | $20.6B | — (loss-making) | — (loss-making) | +36.12% (above 0%: growing) | n/m | +18.74% (above 0%: growing) | 65.42% | (36.78%) | Compare |
| MEDP Medpace Holdings, Inc. | $17.8B | 34.6× | 35.8× | +8.50% (above 0%: growing) | +24.56% (above 0%: growing) | −16.59% (below 0%: shrinking) | 71.39% | 23.12% | Compare |
| RVTY Revvity Inc. | $16.8B | 71.9× | 66.2× | +4.29% (above 0%: growing) | +2.17% (above 0%: growing) | +26.97% (above 0%: growing) | 57.43% | 13.05% | Compare |
| ICLR ICON PLC | $15.1B | 34.5× | 34.6× | −2.86% (below 0%: shrinking) | n/m | −8.01% (below 0%: shrinking) | 24.29% | 9.82% | Compare |
| CRL Charles River Laboratories International, Inc. | $14.9B | 300× | 89.2× | −2.20% (below 0%: shrinking) | +530.30% (above 0%: growing) | +16.29% (above 0%: growing) | 36.42% | 20.62% | |
| QGEN QIAGEN N.V. | $10.5B | 26.1× | 26.0× | +0.28% (above 0%: growing) | +7.94% (above 0%: growing) | +30.45% (above 0%: growing) | 63.62% | 24.75% | Compare |
| Median of peers | $19.2B | 34.5× | 34.6× | +5.61% | +16.25% | +22.86% | 60.53% | 14.26% |
From the latest earnings call
- CEO Birgit Girshick said demand improved in Discovery and Safety Assessment, while reduced proposal discounts would take time to reach revenue.
- CFO Glenn Coleman said Charles River raised its full-year organic revenue and non-GAAP earnings guidance after its third-quarter performance exceeded its outlook.
Largest institutional holders 13F, quarter to 30 June 2026
Held by institutions
119.06%
Held by the ten largest
57.60%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 5.80m | 12.15% | −145.62k |
| Fidelity (FMR) | 4.24m | 8.88% | +783.51k |
| BlackRock | 3.80m | 7.96% | −60.54k |
| Invesco | 2.98m | 6.25% | +587.53k |
| HARRIS ASSOCIATES L P | 2.24m | 4.70% | +87.85k |
| Allspring Global Investments Holdings, LLC | 1.91m | 3.99% | −88.07k |
| State Street | 1.86m | 3.91% | −9.33k |
| Dimensional Fund Advisors | 1.65m | 3.45% | −4.03k |
| T. Rowe Price | 1.51m | 3.15% | +380.23k |
| ARIEL INVESTMENTS, LLC | 1.50m | 3.15% | +62.02k |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Pay and ownership Proxy statement filed 31 March 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 15.44m | 24.91m | 81.00 |
| 2024 | 13.47m | 3.10m | 74.00 |
| 2023 | 14.10m | 20.47m | 94.00 |
| 2022 | 13.45m | 10.66m | 87.00 |
| 2021 | 13.71m | 41.20m | 147.00 |
Ownership
Directors and executive officers, together
1.30%
The Vanguard Group, Inc.
12.10%
BlackRock, Inc.
7.10%
Invesco, Ltd.
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Charles River Laboratories International, Inc. (CRL) Latest News
5 Nov
4 Nov
29 Oct
28 Oct
27 Oct
22 Oct
CRL metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Charles River Laboratories helps pharmaceutical and biotechnology companies research potential medicines and test their safety before human trials. It also supplies research animals and related services to laboratories, and products and testing services used to check the quality of manufactured medicines.
Its work covers several stages of non-clinical development. Researchers can use its discovery services to identify and refine potential drug candidates, then use its safety assessment services to investigate possible harmful effects. These studies can use cells or tissues in laboratory tests, as well as animals bred for research. Charles River also performs laboratory analysis to help clients understand how a drug moves through the body.